Raymond A. Bendele

1.3k total citations · 1 hit paper
15 papers, 1.0k citations indexed

About

Raymond A. Bendele is a scholar working on Molecular Biology, Infectious Diseases and Oncology. According to data from OpenAlex, Raymond A. Bendele has authored 15 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 3 papers in Infectious Diseases and 3 papers in Oncology. Recurrent topics in Raymond A. Bendele's work include DNA Repair Mechanisms (3 papers), Biochemical and Molecular Research (3 papers) and Cancer therapeutics and mechanisms (3 papers). Raymond A. Bendele is often cited by papers focused on DNA Repair Mechanisms (3 papers), Biochemical and Molecular Research (3 papers) and Cancer therapeutics and mechanisms (3 papers). Raymond A. Bendele collaborates with scholars based in United States, United Kingdom and India. Raymond A. Bendele's co-authors include Masahiko Sato, Larry J. Black, George J. Cullinan, William R. Bensch, Raymond F. Kauffman, Ellen R. Rowley, D. Clive Williams, A Bekele, David E. Magee and G Biesecker and has published in prestigious journals such as Journal of Clinical Investigation, Cancer Research and Biochemical Pharmacology.

In The Last Decade

Raymond A. Bendele

14 papers receiving 994 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.

1994 506 citations Larry J. Black, Masahiko Sato et al. Journal of Clinical Investigation profile →

Peers

Countries citing papers authored by Raymond A. Bendele

Since Specialization

Citations

This map shows the geographic impact of Raymond A. Bendele's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raymond A. Bendele with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raymond A. Bendele more than expected).

Fields of papers citing papers by Raymond A. Bendele

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raymond A. Bendele. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raymond A. Bendele. The network helps show where Raymond A. Bendele may publish in the future.

Co-authorship network of co-authors of Raymond A. Bendele

This figure shows the co-authorship network connecting the top 25 collaborators of Raymond A. Bendele. A scholar is included among the top collaborators of Raymond A. Bendele based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raymond A. Bendele. Raymond A. Bendele is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Polymerization of the triphosphates of ara-C, 2’,2’-difluorodeoxycytidine and OSI-7836 (4’-thio-ara-C, S-ara-C) by human DNA polymerase α and DNA primase 2004 ·Cancer Research ·Katherine Richardson, (unknown), Chad L. Moore, John C. Rohloff, Blake Tomkinson, Raymond A. Bendele, Frank C. Richardson, Robert D. Kuchta	1
2	Polymerization of the triphosphates of AraC, 2′,2′-difluorodeoxycytidine (dFdC) and OSI-7836 (T-araC) by human DNA polymerase α and DNA primase 2004 ·Biochemical Pharmacology ·Katherine Richardson, (unknown), Frank C. Richardson, Chad L. Moore, John C. Rohloff, Blake Tomkinson, Raymond A. Bendele, Robert D. Kuchta	32
3	Incorporation of OSI-7836 into DNA of Calu-6 and H460 xenograft tumors 2004 ·Cancer Chemotherapy and Pharmacology ·Frank C. Richardson, Chris Black, Katherine Richardson, (unknown), Edward Wells, (unknown), Gina Sennello, (unknown), Denny Meyer, David Emerson, Eric Brown, (unknown), C. Nilsson, Blake Tomkinson, Raymond A. Bendele	7
4	Quantification of 2‘-Fluoro-2‘-deoxyuridine and 2‘-Fluoro-2‘-deoxycytidine in DNA and RNA Isolated from Rats and Woodchucks Using LC/MS/MS 2002 ·Chemical Research in Toxicology ·Frank C. Richardson, Chenghong Zhang, Sally Lehrman, Hasan Koç, James A. Swenberg, Katherine Richardson, Raymond A. Bendele	26
5	Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice 2001 ·Anti-Cancer Drugs ·John Desjardins, (unknown), David L. Emerson, Blake Tomkinson, (unknown), Eric Brown, Marta Hamilton, (unknown), Mieke Ptaszynski, Raymond A. Bendele, Frank C. Richardson	15
6	Pharmacokinetics and Safety of an Anti-Vascular Endothelial Growth Factor Aptamer (NX1838) Following Injection into the Vitreous Humor of Rhesus Monkeys 2000 ·Pharmaceutical Research ·Daniel W. Drolet, J. Arly Nelson, (unknown), Philip M. Zack, (unknown), (unknown), (unknown), James A. Farmer, Julie Wolf, Stanley C. Gill, Raymond A. Bendele	159
7	Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan. 2000 ·PubMed ·David L. Emerson, Raymond A. Bendele, Eric Brown, (unknown), John Desjardins, (unknown), Stanley C. Gill, Marta Hamilton, (unknown), L Moon-McDermott, (unknown), Frank C. Richardson, Blake Tomkinson, Michael J. Luzzio, David P. Baccanari	51
8	Derivation of RNA aptamer inhibitors of human complement C5 1999 ·Immunopharmacology ·G Biesecker, (unknown), (unknown), Raymond A. Bendele	114
9	An Evaluation of the Toxicities of 2' -Fluorouridine and 2'-Fluorocytidine-HCI in F344 Rats and Woodchucks (Marmota monax) 1999 ·Toxicologic Pathology ·Frank C. Richardson, Bud C. Tennant, Denny J. Meyer, Katherine Richardson, Peter C. Mann, (unknown), Julie Wolf, Philip M. Zack, Raymond A. Bendele	28
10	Anthracycline Efficacy in vitro: Cytotoxicity of Liposomal/Nonliposomal Daunorubicin and Doxorubicin for Multiple Tumor Cell Types 1997 ·Drug Delivery ·Marc E. Wiles, Carol Bell, Darla Landfair, Eric Lynam, Raymond A. Bendele	19
11	Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. breakdown → 1994 ·Journal of Clinical Investigation ·Larry J. Black, Masahiko Sato, Ellen R. Rowley, David E. Magee, A Bekele, D. Clive Williams, George J. Cullinan, Raymond A. Bendele, Raymond F. Kauffman, William R. Bensch	506
12	Safety Assessment Programs for U.S. Regulatory Agencies: A Perspective of Requirements and Compliance 1994 ·Toxicologic Pathology ·Raymond A. Bendele	1
13	Comparisons of protein changes in human and rodent hepatocytes induced by the rat‐specific carcinogen, methapyrilene 1993 ·Electrophoresis ·Frank C. Richardson, Stephen C. Strom, (unknown), Raymond A. Bendele, Gregory S. Probst, N. Leigh Anderson	16
14	Hepatocellular Proliferation in Ibuprofen-Treated Mice 1993 ·Toxicologic Pathology ·Alison M. Bendele, James F. Hulman, Sandy White, (unknown), Raymond A. Bendele	12
15	Carcinogenicity studies of fluoxetine hydrochloride in rats and mice. 1992 ·PubMed ·Raymond A. Bendele, (unknown), Wherly P. Hoffman, Christian L. Gries, Douglas M. Morton	62

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact